OAB & Urgency Urinary Incontinence
Overactive bladder (OAB) and urgency urinary incontinence (UUI) are managed across a menu of treatment categories rather than a strict stepwise ladder — a paradigm shift codified in the AUA / SUFU 2024 guideline on idiopathic OAB, which explicitly eliminated mandatory step therapy in favor of shared decision-making. Reconstructive urologists are typically involved at the procedural and surgical end of this pathway.
Decision Framework
The 2024 AUA / SUFU guideline organizes OAB treatments into six categorical menus from which clinicians and patients select through shared decision-making: behavioral therapies (offered to all — Clinical Principle), non-invasive therapies (may be offered to all — Clinical Principle), pharmacologic therapies (β-3 agonist typically preferred over antimuscarinic given cognitive-risk profile), minimally invasive therapies (SNM, PTNS / iTNM, intradetrusor onabotulinumtoxinA — Moderate Recommendation, Grade A; may be offered without prior trials of behavioral or pharmacologic management), invasive therapies (augmentation cystoplasty, urinary diversion — Expert Opinion, severely impacted patients only), and indwelling catheters as a last resort. OAB is a clinical diagnosis — minimum evaluation is history with validated questionnaire (OAB-q, ICIQ-OAB), 3-day voiding diary, urinalysis, exam, and PVR; urodynamics are not required for initial management.
Treatment Selection by Clinical Scenario
| Clinical Scenario | First-Line Choice | Alternative(s) | Key Considerations |
|---|---|---|---|
| Mild OAB, prefers non-pharmacologic | Behavioral therapy + PFMT ± TTNS | Bladder training alone | Adherence-dependent; safest profile |
| OAB / UUI, first-line pharmacotherapy | β-3 agonist (vibegron or mirabegron) | Antimuscarinic | β-3 preferred — no anticholinergic cognitive burden. Vibegron 100 mg most efficacious for frequency in NMA (Huang 2025) |
| Inadequate response to β-3 monotherapy | Add antimuscarinic (mirabegron 50 + solifenacin 5 — SYNERGY II, BESIDE) | Switch to antimuscarinic | Combination superior to either monotherapy; monitor anticholinergic burden |
| Elderly (≥ 65 yr) or cognitive concerns | β-3 agonist preferred | If antimuscarinic needed: trospium (does not cross BBB) or fesoterodine (only agent not associated with dementia in Sheyn 2025 cohort of 941,402 patients) | Avoid oxybutynin / tolterodine — highest cumulative dose-dependent dementia risk (Malcher 2022 aOR 1.48 at > 365 DDDs) |
| Patient prefers to avoid daily medication | Intradetrusor onabotulinumtoxinA 100 U or SNM or iTNM | PTNS | All three minimally-invasive options now offerable as first-line per 2024 guideline |
| Refractory to pharmacotherapy | BTX 100 U or SNM or iTNM | PTNS (if office-based maintenance feasible) | All three Grade A. BTX most efficacious for UUI cure; SNM most durable; iTNM eliminates office visits |
| Refractory to BTX and neuromodulation | Augmentation cystoplasty | — | Last surgical resort; requires CIC; lifelong surveillance |
| Intractable incontinence, all options exhausted | Urinary diversion or indwelling catheter | — | High morbidity; consider patient goals and comorbidities |
| Male with OAB + BPH | Vibegron (FDA-approved in this population) ± alpha-blocker | Mirabegron | Vibegron specifically studied in men on BPH pharmacotherapy |
Minimally-Invasive Sub-Comparison
When pharmacotherapy fails or is declined, the choice among BTX, SNM, iTNM, and PTNS involves distinct trade-offs:
| Feature | Intradetrusor BTX 100 U | Sacral Neuromodulation (SNM) | Implantable TNS (iTNM) | PTNS |
|---|---|---|---|---|
| UUI responder rate | Highest; greatest UIE reduction in NMA (Drake 2017) | 71.8%; 67–82% success at 5 yr (Siegel 2018) | 71.3%; 79.4% OAB responder (Amundsen 2025) | 68% pooled (Wang 2020 meta) |
| Duration | ~6–9 mo per injection | Continuous (5–15 yr battery) | Continuous (rechargeable) | Ongoing maintenance sessions |
| Reversibility | Wears off | Device removal | Device removal | Fully reversible |
| Trial phase needed | No | Yes (PNE / staged implant) | No | No |
| Key risks | UTI; urinary retention 5.4% — requires CIC capability | Implant-site pain (15%); lead migration; revision 3% / removal 9% | Similar to SNM | Minimal |
| Office burden | Repeat injections q6–9 mo | Low after implant | Low (home-based) | High — weekly + maintenance |
| MRI compatibility | N/A | Newer devices MRI-conditional | MRI-conditional | N/A |
Antimuscarinic Cognitive-Risk Hierarchy
Anticholinergic OAB therapy is associated with cumulative-dose-dependent dementia risk (Malcher 2022 aOR 1.07 at 1–90 DDDs → 1.29 at 91–365 → 1.48 at > 365 DDDs). The AUA / SUFU 2024 guideline recommends discussing dementia risk with all patients prescribed antimuscarinics.
| Cognitive Risk | Agents | Notes |
|---|---|---|
| Lowest (preferred in elderly) | Trospium (quaternary amine, does not cross BBB); Fesoterodine | Trospium showed no dementia signal in Malcher 2022; fesoterodine was the only agent not associated with dementia in any age / sex group in Sheyn 2025 cohort (n = 941,402) |
| Moderate | Darifenacin (M3-selective; theoretical CNS-sparing); Tolterodine ER | Darifenacin showed no cognitive decline in 3 studies |
| Conflicting | Solifenacin | Most efficacious antimuscarinic in NMA (10 mg) but elevated dementia risk in some cohorts |
| Highest | Oxybutynin (avoid in elderly; topical / gel formulations attenuate but do not eliminate risk) | Cognitive decline in 5 / 8 studies; strongest dose-dependent dementia signal |
Stepwise Escalation (Optional / When Patient Defaults to Traditional Approach)
The 2024 guideline eliminates mandatory step therapy, but many patients still prefer a graduated approach:
- Behavioral therapies — bladder training, fluid / caffeine / alcohol modification, urgency suppression, weight loss
- Non-invasive therapies — PFMT ± biofeedback, TTNS, transvaginal electrical stimulation
- Pharmacotherapy — β-3 agonist → antimuscarinic → combination
- Minimally invasive — BTX 100 U, SNM, iTNM, or PTNS
- Augmentation cystoplasty
- Urinary diversion or indwelling catheter
| Treatment | Category | Best for / indication |
|---|---|---|
| Behavioral Therapy (Bladder Training + Urgency Suppression) | Behavioral | First-line for every OAB / UUI patient — should be offered to all (AUA / SUFU 2024). |
| Fluid Management & Dietary Modifications | Behavioral | Universal adjunct — caffeine / alcohol / carbonation / artificial sweeteners. |
| Weight Loss | Behavioral | BMI ≥ 25 — modest UUI benefit (smaller effect than SUI). |
| Pelvic Floor Muscle Training (PFMT) | Non-Invasive | Hypotonic phenotype — strengthening; hypertonic — down-training. Do not equate with Kegels for guarded floors. |
| Transcutaneous Tibial Nerve Stimulation (TTNS) | Non-Invasive | Dry OAB (urgency / frequency without incontinence); home-based therapy. |
| Pelvic Floor Electrical Stimulation | Non-Invasive | Patients who cannot voluntarily contract the pelvic floor; adjunct to PFMT. |
| Beta-3 Agonists (Vibegron / Mirabegron) | Pharmacological | Preferred first-line pharmacotherapy — especially elderly (no anticholinergic cognitive burden). |
| Antimuscarinics | Pharmacological | Younger patients without dementia risk; trospium / fesoterodine in elderly. Avoid oxybutynin. |
| Combination β-3 + Antimuscarinic | Pharmacological | Inadequate response to monotherapy; mirabegron 50 + solifenacin 5 most studied. |
| Intradetrusor OnabotulinumtoxinA (100 U) | Minimally Invasive | Refractory OAB / UUI in CIC-capable patients; greatest reduction in UIE. |
| Sacral Neuromodulation (SNM) | Minimally Invasive | Refractory OAB / UUI; non-obstructive retention; trial phase to predict response. |
| Implantable Tibial Nerve Stimulation (eCoin / Revi) | Minimally Invasive | Refractory OAB / UUI; SNM-comparable efficacy without a trial phase or sacral implant. |
| Percutaneous Tibial Nerve Stimulation (PTNS) | Minimally Invasive | Refractory OAB; patients accepting weekly office visits and ongoing maintenance. |
| Augmentation Cystoplasty (Enterocystoplasty) | Invasive Surgical | Severely impacted patient refractory to all third-line therapies; CIC-tolerant. |
| Urinary Diversion | Invasive Surgical | Last-resort surgical option for intractable incontinence with non-functional bladder. |
| Indwelling Catheter (Urethral or Suprapubic) | Indwelling Catheter | Last resort — patients who have exhausted all options or are too frail for surgery. |